Emmaus Life Sciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

SELECTED FINANCIAL STATEMENT - LIABILITIES (Tables)

3 Months Ended

Mar. 31, 2024

Accounts payable and accrued expenses consisted of the following at March 31, 2024 and December 31, 2023 (in thousands):


	March 31, 2024		December 31, 2023
Accounts payable:
Clinical and regulatory expenses	$	670	$	696
Professional fees		861		721
Selling expenses		1,807		1,498
Manufacturing costs		891		914
Non-employee director compensation		839		766
Other vendors		1,497		1,292
Total accounts payable		6,565		5,887
Accrued interest payable, related parties		587		542
Accrued interest payable		2,516		3,122
Accrued expenses:
Payroll expenses		1,251		1,270
Government rebates and other rebates		7,181		5,881
Due to customers		—		844
Other accrued expenses		87		179
Total accrued expenses		8,519		8,174
Total accounts payable and accrued expenses	$	18,187		17,725

Other current liabilities consisted of the following at March 31, 2024 and December 31, 2023 (in thousands):


	March 31, 2024		December 31, 2023
Trade discount	$	3,500	$	3,000
Unearned revenue (a)		10,000		10,000
Other current liabilities		1,358		1,681
Total other current liabilities	$	14,858	$	14,681

(a) Refer to Note 3 for information regarding to the unearned revenue.

Other long-term liabilities consisted of the following at March 31, 2024 and December 31, 2023 (in thousands):


	March 31, 2024		December 31, 2023
Trade discount	$	16,928	$	17,324
Other long-term liabilities		39		39
Total other long-term liabilities	$	16,967	$	17,363